Table 4 Signal detection for adverse events associated with neuraminidase inhibitors in vulnerable subjects.

From: Assessment of adverse events related to anti-influenza neuraminidase inhibitors using the FDA adverse event reporting system and online patient reviews

Clinical symptoms

Event (n)

PRR (kai2)

ROR (95% CI)

IC

Oseltamivir <19 years

Vomiting

118

8.51 (13.68)

8.3 (2.20, 36.30)

0.19

Hallucination

103

7.43 (11.38)

7.74 (1.90, 31.52)

0.19

Peramivir ≥65 years

Hepatic function abnormal

9

26.08 (77.83)

27.17 (9.02, 81.79)

3.36

Cardiac failure

5

24.14 (41.70)

24.69 (5.86, 104.03)

3.36

Cardio-respiratory arrest

5

18.11 (36.01)

18.51 (4.93, 69.45)

3.21

Shock

5

12.07 (27.79)

12.33 (3.73, 40.75)

2.94

  1. PRR, proportional reporting ratio; ROR, reporting odds ratios; CI, the confidence interval.
Back to article page